CA2071538A1 - Hpth (1-37) fragment, its production, drug containing it and its use - Google Patents
Hpth (1-37) fragment, its production, drug containing it and its useInfo
- Publication number
- CA2071538A1 CA2071538A1 CA2071538A CA2071538A CA2071538A1 CA 2071538 A1 CA2071538 A1 CA 2071538A1 CA 2071538 A CA2071538 A CA 2071538A CA 2071538 A CA2071538 A CA 2071538A CA 2071538 A1 CA2071538 A1 CA 2071538A1
- Authority
- CA
- Canada
- Prior art keywords
- hpth
- fragment
- peptide
- existence
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 title abstract 6
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000004071 biological effect Effects 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 1
- 102000003982 Parathyroid hormone Human genes 0.000 abstract 1
- 108010049264 Teriparatide Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 238000003795 desorption Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000000260 male genitalia Anatomy 0.000 abstract 1
- 238000004949 mass spectrometry Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000849 parathyroid Effects 0.000 abstract 1
- 239000000199 parathyroid hormone Substances 0.000 abstract 1
- 108010073230 parathyroid hormone (1-38) Proteins 0.000 abstract 1
- 239000013558 reference substance Substances 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A human blood peptide, hPTH (1-37), the structure of which has been elucidated, can be used as a drug for diagnostic, medical and industrial purposes. The isolation of an hPTH (38-84) fragment demonstrates the existence of the hPTH (1-37). Removal of amino-terminal amino acids on the hPTH (1-37) reduces its biological activity. The hPTH (1-37) which circulates in the blood is identical to the synthetic reference substance hPTH (1-37), but not fragments such as hPTH (1-33), hPTH (1-34) or hPTH (1-38). The existence of the hPTH (1-37) molecular form was proved by mass spectroscopy (plasma desorption method). A different biological activity and differences in the three-dimensional peptide structure between the hPTH (1-37) fragment and other hPTH fragments prove that this hPTH fragment is the preferred natural peptide of the parathormone family, which should be used for treating diseases of the parathyroids, the circulatory and respiratory systems, the male genital organ and the kidneys.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP3935738.4 | 1989-10-27 | ||
| DE3935738A DE3935738A1 (en) | 1989-10-27 | 1989-10-27 | DRUGS CONTAINING THE HUMAN PARATHORMONE FRAGMENT (1-37) AS AN ACTIVE AGENT |
| PCT/EP1990/001807 WO1991006564A1 (en) | 1989-10-27 | 1990-10-25 | hPTH (1-37) FRAGMENT, ITS PRODUCTION, DRUG CONTAINING IT AND ITS USE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2071538A1 true CA2071538A1 (en) | 1991-04-28 |
| CA2071538C CA2071538C (en) | 2000-09-19 |
Family
ID=6392300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002071538A Expired - Fee Related CA2071538C (en) | 1989-10-27 | 1990-10-25 | Hpth (1-37) fragment, its production, drug containing it and its use |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0497915B1 (en) |
| JP (1) | JP3135122B2 (en) |
| AT (1) | ATE121424T1 (en) |
| AU (1) | AU643725B2 (en) |
| CA (1) | CA2071538C (en) |
| DE (2) | DE3935738A1 (en) |
| DK (1) | DK0497915T3 (en) |
| ES (1) | ES2071837T3 (en) |
| GR (1) | GR3015909T3 (en) |
| WO (1) | WO1991006564A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ302401B6 (en) * | 1997-12-09 | 2011-05-04 | Eli Lilly And Company | Pharmaceutical composition containing stabilized teriparatide solution, process for its preparation and vial containing thereof |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4039656A1 (en) * | 1990-12-12 | 1992-06-17 | Bissendorf Peptide Gmbh | DRUGS, CONTAINING THE HUMAN PARATHORMONE FRAGMENT (1-37) IN THE FORM OF AMIDE OR ETHYLAMIDE AS AN ACTIVE AGENT |
| SK74594A3 (en) * | 1991-12-17 | 1995-01-12 | Procter & Gamble Pharma | Treatment for treating of osteoporosis |
| DE4203040A1 (en) * | 1992-02-04 | 1993-08-05 | Boehringer Mannheim Gmbh | NEW PARATHORMON FRAGMENTS, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM |
| US5496801A (en) * | 1993-12-23 | 1996-03-05 | Allelix Biopharmaceuticals Inc. | Parathyroid hormone formulation |
| DE4434551A1 (en) * | 1994-09-28 | 1996-04-04 | Forssmann Wolf Georg Prof Dr D | Peptides from the sequence of hPTH (1-37) |
| DE19517430A1 (en) * | 1995-05-12 | 1996-11-14 | Boehringer Mannheim Gmbh | Pharmaceutical dosage form of parathyroid hormone with a two to six hour drug release period |
| WO1997018314A1 (en) * | 1995-11-16 | 1997-05-22 | Boehringer Mannheim Gmbh | Process for the preparation of peptides by way of streptavidin fusion proteins |
| SE9702401D0 (en) | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| HU226866B1 (en) * | 1997-09-09 | 2009-12-28 | Hoffmann La Roche | Fracture healing using pthrp analogs |
| US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| SE9801495D0 (en) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulation |
| AR033639A1 (en) | 1998-08-19 | 2004-01-07 | Lilly Co Eli | USE OF PARTIROID HORMONES TO PREPARE MEDICINES TO REDUCE THE RISK OF VERTEBRAL OR NON-VERTEBRAL OSEAS FRACTURES IN HUMAN BEINGS WITH RISK OF SUFFERING OR WHO HAVE OSTEOPOROSIS |
| US20040033950A1 (en) | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
| US7820393B2 (en) | 1999-01-14 | 2010-10-26 | Scantibodies Laboratory, Inc. | Methods, kits and antibodies for detecting parathyroid hormone |
| US6689566B1 (en) | 1999-01-14 | 2004-02-10 | Scantibodies Laboratory, Inc. | Methods, kits, and antibodies for detecting parathyroid hormone |
| WO2004028444A2 (en) | 1999-06-02 | 2004-04-08 | Scantibodies Laboratory, Inc. | Parathyroid hormone antagonists and uses thereof |
| US6923968B2 (en) | 2000-08-10 | 2005-08-02 | Scantibodies Laboratory, Inc. | Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis |
| US7056655B2 (en) | 2001-11-02 | 2006-06-06 | Scantibodies Laboratory, Inc. | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| US6524788B1 (en) | 2001-11-02 | 2003-02-25 | Thomas L. Cantor | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| IN2013MU02726A (en) * | 2013-08-21 | 2015-06-26 | Cadila Healthcare Ltd |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3243358A1 (en) * | 1982-11-24 | 1984-05-24 | Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch | SYNTHETIC HUMANES (1-38) PARATHORMONE FRAGMENT, METHOD FOR THE PRODUCTION THEREOF AND THE USE FOR TREATING THE OSTEOPOROSIS |
| US4771124A (en) * | 1987-05-26 | 1988-09-13 | Merck & Co., Inc. | Parathyroid hormone antagonists with simplified synthetic methodology |
-
1989
- 1989-10-27 DE DE3935738A patent/DE3935738A1/en not_active Withdrawn
-
1990
- 1990-10-25 DK DK90917747.9T patent/DK0497915T3/en active
- 1990-10-25 WO PCT/EP1990/001807 patent/WO1991006564A1/en active IP Right Grant
- 1990-10-25 AU AU68712/91A patent/AU643725B2/en not_active Ceased
- 1990-10-25 JP JP03500084A patent/JP3135122B2/en not_active Expired - Fee Related
- 1990-10-25 EP EP90917747A patent/EP0497915B1/en not_active Expired - Lifetime
- 1990-10-25 DE DE59008949T patent/DE59008949D1/en not_active Expired - Fee Related
- 1990-10-25 AT AT90917747T patent/ATE121424T1/en not_active IP Right Cessation
- 1990-10-25 CA CA002071538A patent/CA2071538C/en not_active Expired - Fee Related
- 1990-10-25 ES ES90917747T patent/ES2071837T3/en not_active Expired - Lifetime
-
1995
- 1995-04-20 GR GR950401002T patent/GR3015909T3/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ302401B6 (en) * | 1997-12-09 | 2011-05-04 | Eli Lilly And Company | Pharmaceutical composition containing stabilized teriparatide solution, process for its preparation and vial containing thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| DK0497915T3 (en) | 1995-09-25 |
| AU6871291A (en) | 1991-05-31 |
| ATE121424T1 (en) | 1995-05-15 |
| ES2071837T3 (en) | 1995-07-01 |
| DE3935738A1 (en) | 1991-05-08 |
| WO1991006564A1 (en) | 1991-05-16 |
| AU643725B2 (en) | 1993-11-25 |
| JPH05505594A (en) | 1993-08-19 |
| EP0497915A1 (en) | 1992-08-12 |
| CA2071538C (en) | 2000-09-19 |
| GR3015909T3 (en) | 1995-07-31 |
| EP0497915B1 (en) | 1995-04-19 |
| DE59008949D1 (en) | 1995-05-24 |
| JP3135122B2 (en) | 2001-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU643725B2 (en) | hPTH (1-37) fragment, its production, drug containing it and its use | |
| Ratnoff et al. | The activation of Christmas factor (factor IX) by activated plasma thromboplastin antecedent (activated factor XI) | |
| GB2108388A (en) | Composition and method for treating alcohol and drug addicts | |
| WO1999012561A3 (en) | FRACTURE HEALING USING PTHrP ANALOGS | |
| EP0526544A4 (en) | Therapeutic uses of actin-binding compounds | |
| ATE204178T1 (en) | METHOD FOR TREATING AND PREVENTING TYPE 1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN | |
| DE3587941D1 (en) | DEVICE FOR PROVISIONAL REPERFUSION TREATMENT OF HEART ATTACK SYMPTOMS. | |
| DE69721203D1 (en) | Process for producing a tissue adhesive, the coagulation of which is carried out by adding calcium ions | |
| AU6642390A (en) | Methods and compositions for promoting immunopotentiation | |
| EP0278776A3 (en) | Methods and deoxyribonucleic acid for the preparation of tissue factor protein | |
| ATE84048T1 (en) | PEPTIDE, ITS METHOD OF MANUFACTURE, PHARMACEUTICAL COMPOSITION AND USE CONTAINING THEM. | |
| DK610888D0 (en) | CARDIODILATE INGREDIENT, METHOD OF PREPARING THEREOF AND ITS USE | |
| CA2134535A1 (en) | Method for sterilizing recombinant human serum albumin pharmaceutical preparation | |
| HUP0002265A2 (en) | Process for producing a plasma protein-containing medicament | |
| DE69433682D1 (en) | AQUEOUS PROTEIN COMPOSITION, CONTAINING GLYCOPROTEINS, METHOD FOR THE PRODUCTION AND USE | |
| WO2002004487A3 (en) | Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses | |
| JPS60258120A (en) | Thymus product and manufacture | |
| ATE115863T1 (en) | USE OF A PREPARATION CONTAINING IMMUNOLOBULIN FOR THE PROPHYLAXIS AND THERAPY OF AIDS IN HUMAN BEINGS. | |
| US3153616A (en) | Method of producing a substance having new strong physiological actions from human or cattle saliva | |
| CA1338499C (en) | Chymotrypsin for the inactivation of prekallikrein activator | |
| ATE184287T1 (en) | DERIVATIVES OF PEPTIDES THERAPEUTICALLY EFFECTIVE IN THE BLOOD CLOTTING CAScade, METHOD FOR THE PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | |
| Gordan | A direct action of parathyroid hormone on dead bone in vitro | |
| HUT41632A (en) | Process for preparing agents for the enhancement of protein absorption | |
| Kotkes et al. | New approaches to the characterization and isolation of migration inhibitory factor (MIF) | |
| ES2015772A6 (en) | Process for obtaining new 5-fluorouracil derivatives, specifically N1-acyl-substituted-N3-orthotoluyl-5- fluorouracil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |